A leading RNAi therapeutics firm.

Koch Institute for Integrative Cancer Study; Lipid Nanoparticle Delivery Systems for the Systemic Delivery of siRNA, by Pieter Cullis, Ph.D., Professor Biochemistry and Molecular Biology at UBC; and, Rational Style of Cationic Lipids for siRNA Delivery: Identifying Crucial Structure/Activity Human relationships, by Michael Wish, Ph.D., Chief Scientific Officer of AlCana. In addition, multiple posters were presented at the meeting providing further improvements on the systemic delivery of RNAi therapeutics. Specifically, data were provided describing the discovery of extra novel lipids; the use of small molecules in both cis and trans configurations to enhance LNP-based delivery; targeting-based techniques with LNPs; and, the achievement of extra-hepatic delivery of siRNAs, including to immune cells and prostate malignancy tumor xenografts, with LNPs.Alexion’s non-GAAP operating expenditures for Q1 2011 had been $85.9 million, compared to $65.2 million for Q1 2010. Non-GAAP research and development expenses for Q1 2011 were $28.1 million, compared to $20.3 million for Q1 2010. The increase in R&D expenses primarily reflected the growth of the business’s clinical trial applications. Non-GAAP offering, general and administrative expenses for Q1 2011 were $57.8 million, compared to $44.9 million for Q1 2010. The increase in non-GAAP SG&A expenses primarily reflected costs associated with the expansion of the Company’s commercial operations in fresh geographies. First One fourth GAAP Financial Outcomes: Alexion reported GAAP net income of $26.8 million, or $0.28 per share, for Q1 2011, including a poor after-tax impact of $6.9 million, or $0.07 per share, from costs linked to the Taligen Therapeutics and Orphatec Pharmaceuticals acquisitions during the quarter, in comparison to Q1 2010 GAAP net gain of $20.9 million, or $0.23 per talk about.